← Back to patent-cliff list
Ecubectedin
Tier C — Watch / tradeEcubectedin
Pharma Mar Sa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：RNA
Indications (approved)：Sarcoma, Solid tumour
Regional status
US
Phase I
2017-09-06
EU
Phase II
2021-06-23
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ecubectedin?
Approved indications include: Sarcoma, Solid tumour.
When does the Ecubectedin patent expire?
No public expiry year is available for Ecubectedin yet; this page updates once verified.
How do I get a quote for Ecubectedin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21